Company Overview
Barinthus Biotherapeutics plc is a biotechnology entity dedicated to the research, development, and commercialization of immunotherapies and vaccines within the United States and the United Kingdom. The company focuses specifically on advancing VTP-1000, an antigen-specific immune tolerance candidate that is currently progressing through Phase I clinical trials. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the firm targets therapeutic solutions for conditions requiring precise immune modulation. The company's total market capitalization stands at $22.47M, while its workforce consists of 14 employees, reflecting a highly lean operational structure typical of early-stage biotech ventures. These valuation and staffing figures indicate that Barinthus is a micro-cap entity with limited revenue generation to date, positioning it as a high-risk, high-potential asset that relies heavily on the successful execution of its clinical pipeline rather than established commercial sales streams.
Financial Health
The company reports no reported revenue for the trailing twelve months, resulting in a net income of $-66,428,000 and an EBITDA of $-55,223,000. The substantial gap between the reported revenue of N/A and the significant net loss reveals a cost structure dominated by research and development expenses and operational overhead rather than product sales. Free cash flow stands at $-28,044,376, indicating that the company is burning through its resources to fund its clinical programs and lacks the immediate financial flexibility to sustain operations without external capital infusion. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is consistent with a pre-revenue stage where costs exceed any minimal sales revenue, rendering traditional profitability metrics inapplicable. Despite the losses, the company holds $70.46M in cash against $11.28M in debt, resulting in a debt-to-equity ratio of 15.19, which suggests a leveraged balance sheet relative to its equity base but provides a robust liquidity buffer for ongoing expenditures. The current ratio is 7.76, indicating a highly conservative stance on short-term liquidity with assets significantly exceeding short-term liabilities. Return on Equity is -65.0% and Return on Assets is -28.1%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a standard characteristic of development-stage biotechnology firms.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of net income, while the forward P/E is -0.48, implying that the market prices the stock based on anticipated future earnings that are currently negative. The price-to-book ratio is 0.30, indicating that the market values the company at roughly 30% of its book value, suggesting the market places little premium on the company's tangible assets relative to its share price. The price-to-sales ratio is N/A because there is no revenue, and the EV/EBITDA stands at 0.66, which serves as an alternative valuation metric reflecting the enterprise value relative to its negative earnings before interest, taxes, depreciation, and amortization. The stock has a 52-week high of $2.92 and a 52-week low of $0.54, providing the range within which the security has traded over the past year. The beta value is -0.62, which is an anomalous negative figure indicating that the stock price moves in an inverse relationship to the broader market, suggesting unique volatility drivers unrelated to general market sentiment.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated commercial revenue to establish a growth trajectory. Consequently, the analysis of whether earnings are growing faster or slower than revenue is not applicable in a traditional sense, as the company is entirely dependent on clinical milestones rather than sales performance for value creation. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status indicates that the company reinvests all available earnings and cash reserves directly back into the research and development of its immunotherapy and vaccine candidates. The overall growth and income profile for Barinthus Biotherapeutics is characterized by zero current income generation and a reliance on capital markets for funding growth, rather than organic revenue expansion or shareholder returns.